Here are the files for the UCSF Phase II high-dose ¹³¹I-MIBG compassionate use protocol for treatment of patients having malignant pheochromocytomas or paragangliomas

MIBG Protocol PDF

MIBG Protocol Stem Cell Harvest PDF

MIBG Protocol Consent Form PDF

In order for ¹³¹I-MIBG therapy to achieve a remission for patients with malignant pheochromocytoma, the tumors must have sufficient uptake of MIBG on diagnostic scans to allow enough ¹³¹I-MIBG to enter tumor cells. Treatment doses up to 500 mCi ¹³¹I-MIBG can be given without cryopreserved blood stem cells. At higher doses, there is a significant risk of severe suppression of the bone marrow. However, peripheral blood stem cell leukophoresis and cryopreservation has made it possible to treat patients with malignant pheochromocytoma more aggressively with ¹³¹I-MIBG, since peripheral blood stem cells may be collected in advance and reinfused in the event of prolonged myelosuppression following high-dose ¹³¹I-MIBG therapy.